Amphastar Pharmaceuticals, Inc. (AMPH) Debt Components
- 2026-06-30: Long-term Debt and Lease Obligation, CurrentUSD $2.49M; Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term Debt and Lease ObligationUSD $609.56M; Long-Term Debt, Maturity, Year OneUSD (m).
- 2026-03-31: Long-term Debt and Lease Obligation, CurrentUSD $1.67M; Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term Debt and Lease ObligationUSD $609.80M; Long-Term Debt, Maturity, Year OneUSD (m).
- 2025-12-31: Long-term Debt and Lease Obligation, CurrentUSD $1.64M; Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term Debt and Lease ObligationUSD $608.75M; Long-Term Debt, Maturity, Year OneUSD (m).
- 2025-12-31: Long-term Debt and Lease Obligation, CurrentUSD (m); Long-term Debt, Excluding Current MaturitiesUSD $619.71M; Long-term Debt and Lease ObligationUSD (m); Long-Term Debt, Maturity, Year OneUSD $1.48M.
Amphastar Pharmaceuticals, Inc. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt and Lease Obligation, Current USD | Long-term Debt, Excluding Current Maturities USD | Long-term Debt and Lease Obligation USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-term Debt USD | Long-term Debt and Lease Obligation, Including Current Maturities USD | Long-Term Debt, Maturity, after Year Five USD |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.49M | (m) | $609.56M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $1.67M | (m) | $609.80M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $1.64M | (m) | $608.75M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $619.71M | (m) | $1.48M | $5.69M | $255.69M | $353.54M | $3.30M | (m) | (m) | (m) |
| 2025-09-30 | $923.00K | (m) | $608.58M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $927.00K | (m) | $607.73M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $224.00K | (m) | $603.86M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $234.00K | (m) | $601.63M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $613.53M | (m) | $50.00K | $1.44M | $5.55M | $255.55M | $350.94M | (m) | (m) | (m) |
| 2024-09-30 | $252.00K | (m) | $596.45M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $249.00K | (m) | $586.85M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $428.00K | (m) | $594.01M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $436.00K | (m) | $589.58M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $603.17M | (m) | $234.00K | $245.00K | $254.00K | $7.44M | $250.00M | (m) | (m) | $345.00M |
| 2023-09-30 | $433.00K | $653.27M | $638.21M | $229.00K | $241.00K | $250.00K | $7.55M | (m) | (m) | (m) | $645.00M |
| 2023-06-30 | $12.92M | (m) | $488.28M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $2.17M | (m) | $72.87M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $3.05M | (m) | $72.84M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $76.64M | (m) | $2.85M | $3.73M | $4.18M | $58.44M | $7.44M | (m) | (m) | (m) |
| 2022-09-30 | $1.68M | (m) | $74.01M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $2.06M | (m) | $73.87M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $2.16M | (m) | $74.35M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $2.20M | (m) | $74.78M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $78.19M | (m) | $1.97M | $2.41M | $3.74M | $4.18M | $58.44M | (m) | (m) | $7.44M |
| 2021-09-30 | $2.26M | (m) | $75.55M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $8.08M | (m) | $30.46M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $12.17M | (m) | $32.33M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $12.26M | (m) | $34.19M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $45.92M | (m) | $11.95M | $7.45M | $5.67M | $3.07M | $1.27M | (m) | (m) | $16.52M |
| 2020-09-30 | $12.17M | (m) | $32.90M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $12.07M | (m) | $34.62M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $11.46M | (m) | $36.41M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $7.74M | (m) | $39.39M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $46.32M | (m) | $7.38M | $9.67M | $5.84M | $3.98M | $2.02M | (m) | (m) | $17.43M |
| 2019-09-30 | $6.97M | (m) | $38.08M | (m) | (m) | (m) | (m) | (m) | (m) | $45.05M | (m) |
| 2019-06-30 | $6.94M | (m) | $39.79M | (m) | (m) | (m) | (m) | (m) | (m) | $46.73M | (m) |
| 2019-03-31 | $17.59M | (m) | $30.97M | (m) | (m) | (m) | (m) | (m) | (m) | $48.56M | (m) |
| 2018-12-31 | $18.23M | (m) | $31.98M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $50.21M | (m) |
| 2018-12-31 | (m) | $49.10M | (m) | $17.89M | $3.86M | $6.45M | $2.48M | $458.00K | (m) | (m) | $17.97M |
| 2018-09-30 | $18.59M | (m) | $32.61M | (m) | (m) | (m) | (m) | (m) | (m) | $51.20M | (m) |
| 2018-06-30 | $18.89M | (m) | $33.70M | (m) | (m) | (m) | (m) | (m) | (m) | $52.59M | (m) |
| 2018-03-31 | $6.06M | (m) | $39.71M | (m) | (m) | (m) | (m) | (m) | (m) | $45.77M | (m) |
| 2017-12-31 | $6.31M | (m) | $40.84M | (m) | (m) | (m) | (m) | (m) | (m) | $47.16M | (m) |
| 2017-12-31 | (m) | $45.72M | (m) | $5.99M | $14.91M | $1.81M | $4.40M | $450.00K | (m) | (m) | $18.17M |
| 2017-09-30 | $6.21M | (m) | $42.23M | (m) | (m) | (m) | (m) | (m) | (m) | $48.44M | (m) |
| 2017-06-30 | $6.21M | (m) | $40.11M | (m) | (m) | (m) | (m) | (m) | (m) | $46.31M | (m) |
| 2017-03-31 | $5.26M | (m) | $31.15M | (m) | (m) | (m) | (m) | (m) | (m) | $36.41M | (m) |
| 2016-12-31 | $5.37M | (m) | $32.36M | (m) | (m) | (m) | (m) | (m) | (m) | $37.72M | (m) |
| 2016-12-31 | (m) | $36.03M | (m) | $5.00M | $4.70M | $14.15M | $1.07M | $7.91M | (m) | (m) | $3.19M |
| 2016-09-30 | $8.54M | (m) | $34.16M | (m) | (m) | (m) | (m) | (m) | (m) | $42.70M | (m) |
| 2016-06-30 | $10.90M | (m) | $31.74M | (m) | (m) | (m) | (m) | (m) | (m) | $42.65M | (m) |
| 2016-03-31 | $11.18M | (m) | $29.09M | (m) | (m) | (m) | (m) | (m) | (m) | $40.27M | (m) |
| 2015-12-31 | $10.93M | (m) | $30.16M | (m) | (m) | (m) | (m) | (m) | (m) | $41.10M | (m) |
| 2015-12-31 | (m) | $40.30M | (m) | $10.64M | $4.77M | $3.92M | $13.37M | $291.00K | $40.30M | (m) | $7.30M |
| 2015-09-30 | $14.76M | (m) | $31.35M | (m) | (m) | (m) | (m) | (m) | (m) | $46.12M | (m) |
| 2015-06-30 | $12.63M | (m) | $34.80M | (m) | (m) | (m) | (m) | (m) | (m) | $47.43M | (m) |
| 2015-03-31 | $12.53M | (m) | $35.89M | (m) | (m) | (m) | (m) | (m) | (m) | $48.42M | (m) |
| 2014-12-31 | $7.59M | (m) | $36.11M | (m) | (m) | (m) | (m) | (m) | (m) | $43.70M | (m) |
| 2014-12-31 | (m) | $42.68M | (m) | $7.24M | $12.97M | $3.13M | $2.20M | $13.08M | $42.68M | (m) | $4.05M |
| 2014-09-30 | $10.08M | (m) | $41.27M | (m) | (m) | (m) | (m) | (m) | (m) | $51.35M | (m) |
| 2014-06-30 | $10.66M | (m) | $42.85M | (m) | (m) | (m) | (m) | (m) | (m) | $53.52M | (m) |
| 2013-12-31 | $22.10M | (m) | $10.07M | (m) | (m) | (m) | (m) | (m) | (m) | $32.17M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |